繁
简
Market+ (iPhone)
Market+ (Android)
Mobile Site
US STOCKS
FUNDS
FX & CRYPTO
SH/SZ-HK
HK STOCKS
 
 
 
 
 
 
Quote Service
Market
Market
Quotes
Quotes
Analysis
Analysis
Commentary
Commentary
Warrants&CBBCs
Warrants&CBBCs
Warrants&CBBCs Overview
Warrants
CBBCs
ETF
ETF
MPF
MPF
Education
Members
Members
About Us
About Us

IPO Plus - IPO

To-be Listed (Grey Market Trading Session: 16:15-18:30)
Name▼
/
Code▲
 Industry Listing Price Lot Size Entry Fee Phillip Grey Market Futu (HK) Grey Market
Xunfei Healthcare
02506.HK
Grey Market Today
 Application Software 82.800 50 N/A
-
-
 Detail Quote
InnoScience
02577.HK
Grey Market Today
 Semiconductors & Semiconductor Equipment Pending 100 3,400
-
-
 Detail Quote
HealthyWay
02587.HK
Grey Market Today
 Health Care Services Pending 500 4,444
-
-
 Detail Quote
Last update: 2024-12-26 12:30:05
Name▼
/
Code▼
 Industry Offer Price Lot Size Entry Fee Closing Date
Grey Market Date▼
Listing Date▲
Minieye Tec
02431.HK		 Application Software 17-20.2 200 4,081 2024/12/20 Data is not available 2024/12/27
MEDSCI (02415.HK)
Summary
We operate online professional physician platforms in China. As of December 31, 2022, our platform had approximately 2.9 million registered physician users and our average MAU reached approximately 2.7 million in 2022. Our MedSci platform also features a high percentage of experienced physicians with the title of associate-chief physician (副主任醫師) and above. As of December 31, 2021, the total number of registered physician users on our MedSci platform who had the title of associate-chief physician and above represented 67.1% of the total number of physicians in China who had obtained the title of associate-chief physician and above, based on the latest published information from the NHC. Our MedSci platform is accessible through multiple channels such as website, mobile application, WeChat mini-program and WeChat public account. While key functions of the MedSci platform are self-developed by us, third parties, primarily pharmaceutical and medical device companies, also provide ancillary support, such as academic medical contents they created or copyrighted.

As illustrated by the diagram below, we mainly provide physician platform solutions, precision omni-channel marketing solutions and RWS solutions to our customers. We believe such solution offerings can help generate and share meaningful medical evidence to a wider physician community and help guide prescription decisions of physicians in order to promote the rational use of medical products and deliver better value and care to patients. We are committed to solidifying our position as a platform-based, professional-knowledge-oriented and digitalized med-tech company and aspire to enhance the overall quality of patients’ healthcare through the value offered by generating and sharing medical evidence.

Our solution offerings address the needs and demands of our customers. Our main businesses cover:

‧Precision Omni-channel Marketing Solutions. Benefiting from our large physician user base and high percentage of experienced physician users, we believe we are the platform of choice for pharmaceutical and medical device companies to conduct digital marketing. During the Track Record Period, we primarily generated revenue from the provision of precision omni-channel marketing solutions to pharmaceutical and medical device companies.

Precision Detailing Services. Aided by our academic medical expertise and big data capabilities, we deliver academic medical contents designed in collaboration with pharmaceutical and medical device companies as well as other relevant academic medical contents to target groups of physicians through our MedSci platform based on criteria specified by pharmaceutical and medical device companies accurately and cost-effectively.

Medical Content Creation Services. Enabled by academic medical expertise, we offer medical content creation services through which we design customized highly professional academic medical contents, primarily on products from pharmaceutical and medical device companies based on the stage of the relevant product’s life cycle, its competitive position, the prescription patterns of target physicians and other relevant factors. We may either deliver the academic medical contents created directly on our MedSci platform or in other channels, such as in offline conferences held, through precision detailing services as specified by our customers.

Online Survey Services. We offer online survey services to pharmaceutical and medical device companies by providing a customized electronic survey that targets specific groups of physicians on our MedSci platform based on the specialty, academic background, seniority, interest, geographical location and other factors requested specifically by pharmaceutical and medical device companies. Our survey questionnaires are carefully designed to gauge physicians’ attitudes towards specified products such that pharmaceutical and medical device companies can gain meaningful insights on physicians’ perceptions on medical products. As a result, such pharmaceutical and medical device companies can, with the results from our online survey services, optimize their products and marketing strategies to improve sales.

See ‘‘Business — Our Value Propositions — Value Propositions to Pharmaceutical and Medical Device Companies’’ and ‘‘Business — Our Value Propositions — Value Propositions to Physicians’’ for additional benefits of our precision omni-channel marketing solutions for pharmaceutical and medical device companies and physicians.

‧Physician Platform Solutions. Our physician platform solutions primarily include medical knowledge services through which we provide the latest medical knowledge information to physicians and clinical study assistance services through which we support physicians during their clinical studies.

Medical Knowledge Services. Our MedSci platform provides a setting for physicians to learn and share the latest medical knowledge information and medical evidence in the healthcare market. We offer and screen useful information from various sources and are committed to accurately delivering quality and targeted academic medical contents to physicians, saving their time and efforts required to filter medical knowledge information. See ‘‘Business — Our Value Propositions — Value Propositions to Physicians’’ for additional benefits of our medical knowledge services to physicians. As of December 31, 2022, our platform featured over 15,800 videos that share medical knowledge, covered over 644,000 research findings, created approximately 195,000 materials on the latest medical development and established over 127,500 online discussion forums for physicians to exchange cases and research findings. Most of the contents on our MedSci platform are offered free of charge and we charge physician users subscription fees or per-download fees only for certain premium contents.

Clinical Study Assistance Services. We also provide clinical study assistance to physicians in their investigator-initiated trials (‘‘IITs’’) and other non-registered clinical trials. While certain documentation, such as the protocols we helped designed, are delivered through email directly, our clinical study assistance services are primarily delivered through our MedSci platform by providing required software tools, offering supporting analysis and giving insights on academic medical papers in designated interfaces within our MedSci platform pursuant to our agreements with our physician customers. Physicians can easily access deliverables and track progress of our services by using our MedSci platform. See ‘‘Business — Our Value Propositions — Value Propositions to Physicians’’ for additional benefits of our clinical study assistance services to physicians.

‧RWS Solutions. Our RWS solutions primarily involve offering real-world evidence-based research to pharmaceutical and medical device companies regarding their products’ safety and effectiveness. We help design overall RWS protocols, provide assistance in recruiting and obtaining ethical approvals from participating physicians, researchers and hospitals and generate meaningful insights that can improve the understanding of not only the products being studied, but also the diseases generally, in order to provide our customers with information to potentially help them expand the respective indications of their products. Furthermore, our RWS solutions can also form the basis of academic medical contents that are meaningful for physicians, enabling pharmaceutical and medical device companies to better market their medical products with more information and data collected during RWS. See ‘‘Business — Our Value Propositions — Value Propositions to Pharmaceutical and Medical Device Companies’’ for additional benefits of our RWS solutions to pharmaceutical and medical device companies. Our RWS solutions include assisting pharmaceutical and medical device companies in designing RWS protocols, administrating the project operation, collecting, assessing and analyzing the clinical or real-world data obtained and transforming findings discovered into rigorous academic materials. While documentations generated during RWS solutions may be provided through emails, tools offered as part of our RWS solutions, such as iClinical Station, ePRO and eDiary, are delivered through our MedSci platform. Moreover, leveraging the large physician user base, we can efficiently help pharmaceutical and medical device companies locate physicians and medical institutions that are suited for their RWS.

‧Other Products and Services. We are in the process of launching various other products and services, to physicians, hospitals and non-profit organizations. For instance, we intend to offer (i) digital therapy programs, which are expected to be launched between 2023 and 2025, for the clinical treatment of insomnia, (ii) VR diagnosis products, which are expected to be launched in the fourth quarter of 2023, through which physicians can better use their time in the clinical study of rare diseases, (iii) prognosis modelling services, which are expected to be launched in the fourth quarter of 2023, on complications for rare diseases such that early prevention measures can be taken and (iv) chronic disease management services, which are expected to be launched in the fourth quarter of 2023, that facilitate better treatment outcomes for patients. We intend to receive relevant service fees or subscription fees from our customers for the other products and services provided. We intend to deliver the above mentioned other products and services on our MedSci platform as digital tools. See ‘‘Business — Our Business Services — Other Products and Services’’ for more details.



Source: MedSci Healthcare (02415) Prospectus (IPO Date : 2023/04/17)
Listing Market MAIN
Industry Health Care Services
Background Others
Major Business Area N/A
Corporate Information
Substantial Shareholders Li Xinmei (56.50%)
Hu Xubo & Associates (10.87%)
Meiyue Limited (6.89%)
[00700] Tencent Holdings Limited (6.21%)
Directors Zhang Fabao (Chairman and Executive Director)
Wang Shuai (Vice President and Co-Chief Executive Officer and Executive Director)
Li Xinmei (Chief Executive Officer and Executive Director)
Cheng Liang (Executive Director)
Yan Shengfeng (Non-Executive Director)
Wang Xin (Non-Executive Director)
Lau Yiu Kwan Stanley (Independent Non-Executive Director)
Liu Tao (Independent Non-Executive Director)
Yu Mingyang (Independent Non-Executive Director)
Company Secretary Kwan Sau In
Yang Chun
Principal Bankers China Merchants Bank
China Construction Bank Corporation
China Everbright Bank
Bank of Shanghai
CMB Wing Lung Bank Limited
Solicitors Commerce & Finance Law Offices
Eric Chow & Co. in Association with Commerce & Finance Law Offices
Auditors Ernst & Young
Registered Office 5th Floor, Manulife Place, 348 Kwun Tong Road, Kowloon, Hong Kong
Share Registrars Tricor Investor Services Ltd. [Tel: (852) 2980-1333]
Share Registrars Tel No (852) 2980-1333
Internet Address http://ir.medsci.cn
Email Address ir@medsci.cn
Tel No (86 21) 5448-0588
Fax No
 
SITEMAP
AASTOCKS.com
 
 
Members
 
About Us
Market
Quotes
 
Analysis
News & Research
 
Commentary
 
Warrants&CBBCs
 
Warrants
 
CBBCs
 
US Stocks
Forex
 
Fund
 
MPF
Email: support@aastocks.com
AASTOCKS.COM LIMITED (阿斯達克網絡信息有限公司) All rights reserved.
Disclaimer
You expressly agree that the use of this app/website is at your sole risk.

AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd, Nasdaq, Inc., their respective holding companies and/or any subsidiaries of such holding companies, their Sources and/or other third party data provider(s) endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co.Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) make any express or implied offers, representations or warranties (including, without limitation, any warranty or merchantability or fitness for a particular purpose or use) regarding the Information.

Neither AASTOCKS.com Limited, HKEx Information Services Limited, China Investment Information Services Limited, Shenzhen Securities Information Co. Ltd., Nasdaq, Inc. nor their respective holding companies and/or any subsidiaries of such holding companies nor their Sources and/or other third party data provider(s) will be liable to any Subscriber or any other party for any interruption, inaccuracy, error, or omission, regardless of cause, in the Information or for any damages (whether direct or indirect, consequential, punitive, or exemplary) resulting from its use by any party.

AASTOCKS.com Limited shall not be liable for any failure or delay in performance of its obligations under this Disclaimer because of circumstances beyond its reasonable control, including but without limitation, acts of God, typhoons, rainstorms, other natural disasters, government restrictions, strikes, wars, virus outbreak, network failures or telecommunications failures.

Morningstar Disclaimer: Copyright © 2020 Morningstar, Inc. All Rights Reserved. The information, data, analyses and opinions ("Information") contained herein: (1) include the proprietary information of Morningstar and Morningstar’s third party licensors; (2) may not be copied or redistributed except as specifically authorised; (3) do not constitute investment advice; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Morningstar is not responsible for any trading decisions, damages or other losses related to the Information or its use. Please verify all of the Information before using it and don’t make any investment decision except upon the advice of a professional financial adviser. Past performance is no guarantee of future results. The value and income derived from investments may go down as well as up.

The information and contents contained in this app/website are based on the analyses and interpretations of publicly available information obtained from sources believed to be reliable. Such analyses and information have not been independently verified and AASTOCKS.com Limited makes no guarantees to their accuracy, completeness, timeliness or correctness.

The information, financial market data, quotes, charts, statistics, exchange rate, news, research, analysis, buy and sell ratings, Education Center and other information on this app/website should be used as references only at your own discretion. Prior to the execution of a security or any other trade based upon the Information, you are advised to consult independent professional advice to verify pricing information or to obtain more detailed market information. AASTOCKS.com Limited is not soliciting any subscriber or app/website visitor to execute any trade. Any trades executed following the said information, commentaries and/or buy/sell ratings on this app/website are taken at your own risk for your own account.

AASTOCKS.com Limited provides the information and services on an "AS IS" basis. The information and contents on this app/website are subject to change without notice. AASTOCKS.com Limited reserves the right, in its sole discretion but without any obligation, to make improvements to, or correct any error or omissions in any portion of this app/website at any time.

The subscriber or app/website visitor agrees not to reproduce, retransmit, disseminate, distribute, broadcast, publish, circulate, sell or commercially exploit the information and contents on this app/website in any manner without the express written consent of AASTOCKS.com Limited.

Investment involves risk. You may make use of the Education Center of this website for academic reference purposes at your own discretion. AASTOCKS.com Limited cannot and does not give any assurance that the present or future buy/sell commentaries and signals on this app/website will be profitable. AASTOCKS.com Limited cannot guarantee, and the subscriber or app/website visitor should not assume, that the future performance will equal past performance.

AASTOCKS.com Limited may point to other sites that may be of interest to the subscriber or app/website visitor but for which AASTOCKS.com Limited has no responsibility and only provides this as a service to the subscriber or app/website visitor.

AASTOCKS.com Limited does not represent or endorse the accuracy or reliability of any information, advertisements or contents contained on, distributed through, or linked, downloaded or accessed from any of the services on this app/website. AASTOCKS.com Limited cannot and does not guarantee the quality or reliability of any products or information purchased or obtained by you as a result of an advertisement or any other information displayed on this app/website.

AATV is a video platform owned by AASTOCKS.com Limited.

You acknowledge that: (i) AATV is provided for information purposes only and, in particular, is not intended for trading purposes; (ii) AATV does not and none of the information contained in its program constitutes a solicitation, offer, opinion, or recommendation by us to buy or sell any security, or to provide legal, tax, accounting, or investment advice or services whether or not regarding the profitability or suitability of any security or investment; and (iii) AATV is not intended for use by, or distribution to, any person or entity in any jurisdiction or country where such use or distribution would be contrary to law or regulation.

The financial analysis or opinion expressed in the AATV programs is for reference and discussion only, and does not represent AASTOCKS.com Limited. Investors must make their own investment decisions based on their own investment objectives and financial situation. AASTOCKS.com Limited shall not, directly or indirectly, be liable, in any way, to you or any other person for any: (i) inaccuracies or errors in or omissions from AATV including, but not limited to, quotes and financial data; (ii) delays, errors, or interruptions in the transmission or delivery of AATV; or (iii) loss or damage arising therefrom or occasioned thereby, or by any reason of nonperformance.

AASTOCKS.com Limited reserves the right to change this Disclaimer at any time by posting changes online at this app/website. You are responsible for reviewing regularly information posted therein to obtain timely notice of such changes. Your continued use of this app / website after changes are posted constitutes your acceptance of this Agreement as modified by the posted changes.

The disclaimer herein shall be governed by the law of the Hong Kong Special Administrative Region of the People's Republic of China ("Hong Kong") and you agree to submit to the exclusive jurisdiction of the Hong Kong courts.

In the event of any discrepancy between the Chinese and English versions, the English version shall prevail.

Last updated on 6 January 2023.